Eptinezumab's Impact on Work Productivity in Migraine Patients
Author Information
Author(s): Barbanti Piero, Awad Susanne F., Rae-Espinoza Heather, Regnier Stephane A., Lee Xin Ying, Goadsby Peter J.
Primary Institution: IRCCS San Raffaele, Rome, Italy
Hypothesis
What is the impact of eptinezumab on work productivity in adults with migraine who have had prior treatment failures?
Conclusion
Eptinezumab significantly decreased absenteeism and presenteeism in migraine patients, highlighting the importance of considering the most bothersome symptom.
Supporting Evidence
- Eptinezumab-treated patients had a modeled reduction of 7.2 hours/month in absenteeism compared to placebo.
- Eptinezumab-treated patients experienced a reduction of 21.4 hours/month in presenteeism compared to placebo.
- Improvements in work productivity were observed even after controlling for monthly migraine days.
- Patients reported a substantial negative impact of migraine on work life and productivity.
Takeaway
Eptinezumab helps people with migraines work better by reducing the time they miss work and improving how well they can work when they have a migraine.
Methodology
The study used electronic diaries to capture monthly migraine days and work productivity metrics from patients in a randomized, double-blind, placebo-controlled trial.
Potential Biases
Some patients may have adjusted their schedules to accommodate migraines, potentially affecting response rates.
Limitations
The study population was primarily White and female, which may limit generalizability.
Participant Demographics
The study included adults with migraine and 2-4 prior preventive treatment failures, primarily White and female.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI: −9.9, −4.5 for absenteeism; 95% CI: −26.3, −16.5 for presenteeism
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website